8.37 USD
↗ 0.09 (1.09%)AT CLOSE (11:59 AM EDT)
Xeris Biopharma Holdings, Inc. Common Stock
XERSNASDAQ • USD
8.40
↗ 0.03 (0.36%)
POST MARKET (AS OF 07:24 PM EDT)
Post Market
AS OF 07:24 PM EDT
8.40
↗ 0.03 (0.36%)
Market: CLOSED
Xeris Biopharma Holdings, Inc. Common Stock (XERS) trades at $8.36 per share. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (92.3%) and a bearish Death Cross on the long-term moving averages. On the valuation front, XERS trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jul 6, 2026.
Open?$8.20
High?$8.50
Low?$8.20
Prev. Close?$8.28
Volume?1.9M
Avg. Volume?2.0M
VWAP?$8.41
Rel. Volume?0.97x
Bid / Ask
Bid?$8.09 × 500
Ask?$8.45 × 1.0K
Spread?$0.36
Midpoint?$8.27
Valuation & Ratios
Market Cap?1.4B
Shares Out?172.6M
Float?166.8M
Float %?96.6%
P/E Ratio?120.34
P/B Ratio?111.06
EPS?$0.07
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Employees
435
Market Cap
1.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2018-06-21
Address
1375 WEST FULTON STREET, SUITE 1300
CHICAGO, IL 60607
Phone: 844-445-5704
CHICAGO, IL 60607
Phone: 844-445-5704
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?77
Z-Score?18
Momentum?94
Short Sent.?34
Piotroski F-Score?6/9Mixed
Altman Z-Score?1.39Distress
Confidence?53%Low
Short InterestHigh
Short % of Float?7.68%Elevated
Short Interest?12.8M
Days to Cover?7.3
Free Float166.8M
Avg Daily Volume1.7M
Settlement Date2026-06-15
Financial Health
Current Ratio?2.12Strong
Quick Ratio?1.50Adequate
Cash Ratio?0.94Adequate
Debt/Equity?17.00High
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?120.3PRICEY▾
Peers100
S&P3
P/B?111.06HIGH▾
Peers100
S&P3
P/S?4.59FAIR▾
Peers100
S&P32
P/FCF?30.4FAIR▾
Peers100
S&P28
EV/EBITDA?32.3HIGH▾
Peers100
S&P9
EV/Sales?4.94FAIR▾
Peers100
S&P36
Returns & Efficiency
ROE?92.3%STRONG▾
Peers50
S&P97
ROA?3.1%FAIR▾
Peers50
S&P28
Cash Flow & Enterprise
FCF?$47.5M
Enterprise Value?$1.6B
Fundamentals ratios updated end of day